23andMe Just Sold Your DNA to Big Pharma — No Opt-In Required
In a move that’s raising serious questions about privacy, ethics, and data ownership, genetic testing company 23andMe has officially been acquired by pharmaceutical giant Regeneron for a cool $256 million. On the surface, it looks like just another corporate buyout. But under the hood, it’s something bigger—and more unsettling. It’s a deal that turns your…
